Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2008-08-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT00642915
- Locations
- 🇧🇷
Sanofi-Aventis, Sao Paulo, Brazil
Japanese Study Evaluating the Effects of Telithromycin in Children With Acute Otitis Media
- Conditions
- Otitis Media
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2009-10-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 56
- Registration Number
- NCT00638534
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia
- Conditions
- Pneumonia
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2009-10-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 56
- Registration Number
- NCT00638859
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Once Daily Given Alfuzosin in the Treatment of BPH
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT00637715
- Locations
- 🇭🇺
Sanofi-Aventis, Budapest, Hungary
Leflunomide in Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Eythematosus (SLE)
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2008-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 27
- Registration Number
- NCT00637819
- Locations
- 🇭🇰
Sanofi-Aventis, Hong Kong, Hong Kong
Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 72
- Registration Number
- NCT00637455
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen
- Conditions
- Allergic Rhinitis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT00638118
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms
- Conditions
- Cat Induced Allergic Rhinitis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 70
- Registration Number
- NCT00637884
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
- Conditions
- Allergic Rhinitis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 42
- Registration Number
- NCT00637585
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1010
- Registration Number
- NCT00637611
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States